Balofloxacin is a broad-spectrum, third-generation fluoroquinolone antibiotic. It is a DNA gyrase inhibitor with enhanced activity against Gram-positive bacteria and atypical pathogens compared to earlier fluoroquinolones. It is particularly noted for its once-daily dosing, good tissue penetration, and a favorable safety profile with a lower incidence of phototoxicity and CNS effects. In India, it is primarily used for community-acquired respiratory and urinary tract infections.
Adult: 400 mg once daily. For mild to moderate infections, a 200mg once daily dose may be used as per physician discretion. Typically administered for 5-10 days depending on infection severity and site.
Note: To be taken orally, with or without food. Should be swallowed whole with a full glass of water. Maintain adequate hydration. Do not take with dairy products, calcium-fortified juices, or antacids containing divalent/trivalent cations (Al, Mg, Ca, Fe, Zn) as they significantly reduce absorption. Maintain a minimum 2-hour gap.
Balofloxacin is a bactericidal antibiotic. Its primary mechanism involves inhibition of two essential bacterial type II topoisomerase enzymes: DNA gyrase (primarily in Gram-negative bacteria) and topoisomerase IV (primarily in Gram-positive bacteria).
Pregnancy: Category C (US FDA). Animal studies have shown fetal toxicity (cartilage damage). There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Generally contraindicated.
Driving: May cause dizziness, lightheadedness, or visual disturbances. Patients should be cautioned about operating machinery or driving until they are sure they are not affected.
| Antacids (Aluminum, Magnesium), Sucralfate, Multivitamins/Minerals (Iron, Zinc, Calcium) | Form chelation complexes, drastically reducing balofloxacin absorption. | Major |
| Didanosine (buffered formulation) | Contains aluminum/magnesium buffers; reduces absorption. | Major |
| Warfarin | May enhance anticoagulant effect, increasing INR and bleeding risk. | Major |
| NSAIDs (e.g., Ibuprofen, Aspirin) | May increase the risk of CNS stimulation and seizures. | Moderate |
| Oral Hypoglycemics (Sulfonylureas) / Insulin | May enhance hypoglycemic effect; monitor blood glucose. | Moderate |
| Corticosteroids (Systemic) | Increased risk of tendon rupture, especially in elderly. | Major |
| Other QT-prolonging drugs (e.g., Amiodarone, Sotalol, Macrolides, TCAs, Antipsychotics) | Additive risk of QT prolongation and cardiac arrhythmias. | Major |
| Probenecid | May reduce renal tubular secretion of balofloxacin, increasing its plasma levels. | Moderate |